Equities Analysts Set Expectations for BHC Q3 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Stock analysts at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Tuesday, December 17th. Zacks Research analyst R. Department now anticipates that the company will earn $1.15 per share for the quarter, up from their prior estimate of $1.12. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2025 earnings at $1.25 EPS.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. The firm had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.03 EPS.

Several other equities research analysts also recently weighed in on BHC. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Royal Bank of Canada raised their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Friday, November 1st. Finally, StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.75.

Bausch Health Companies Price Performance

Shares of NYSE BHC opened at $7.39 on Friday. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The firm has a 50-day simple moving average of $8.35 and a two-hundred day simple moving average of $7.27. The company has a market cap of $2.67 billion, a P/E ratio of -15.40 and a beta of 0.69.

Institutional Trading of Bausch Health Companies

A number of institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in shares of Bausch Health Companies by 20.5% in the third quarter. Geode Capital Management LLC now owns 636,082 shares of the company’s stock worth $6,448,000 after buying an additional 108,269 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Bausch Health Companies during the third quarter valued at $938,000. Readystate Asset Management LP increased its position in shares of Bausch Health Companies by 38.1% in the 3rd quarter. Readystate Asset Management LP now owns 470,761 shares of the company’s stock valued at $3,841,000 after acquiring an additional 130,000 shares during the period. Redwood Investment Management LLC raised its stake in Bausch Health Companies by 7.5% in the 3rd quarter. Redwood Investment Management LLC now owns 460,417 shares of the company’s stock worth $3,803,000 after acquiring an additional 31,976 shares during the last quarter. Finally, Maple Rock Capital Partners Inc. acquired a new stake in Bausch Health Companies during the 3rd quarter worth about $16,850,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.